Evidence map›Paper›PMID 37197426›Full record

ArticleFrontiers in oncology2023

Case Report: Infectious prophylaxis in hematological malignancies.

Mauro Passucci, Chiara Masucci, Francesca Paoletti, Claudia Ielo, Alessandro Costa, Ida Carmosino, Emilia Scalzulli, Maurizio Martelli, Giuseppe Gentile, Massimo Breccia

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mauro PassucciDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Chiara MasucciDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Francesca PaolettiDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Claudia IeloDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Alessandro CostaHematology Unit, Businco Hospital, ARNAS G. Brotzu, Cagliari, Italy.
Ida CarmosinoDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Emilia ScalzulliDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Maurizio MartelliDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Giuseppe GentileDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Massimo BrecciaDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · ITAzienda Ospedaliera G. Brotzu · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.

Indexed as

HBV reactivationmyelofibrosisprophylaxisruxolitinibtenofovir

Identifiers

PMID37197426
PMCPMC10183604
OpenAlexW4367624688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.